Ryanodinopathies. RyR-linked muscle diseases

Current Topics in Membranes

Volumn 66, Issue C, 2010, Pages 139-167

  Wei, Lan ^a   Dirksen, Robert T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Calcium channels; Calcium signaling; Cardiac muscle; Catecholaminergic polymorphic ventricular tachycardia; Central core disease; Malignant hyperthermia; Ryanodine receptor; Skeletal muscle

Indexed keywords

EID: 77955102862     PISSN: 10635823     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1063-5823(10)66007-3     Document Type: Chapter

References (120)

1. Arbogast S., Beuvin M., et al. Oxidative stress in SEPN1-related myopathy: From pathophysiology to treatment. Annals of Neurology 2009, 65:677-686.
2. Avila G., Dirksen R.T. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. The Journal of General Physiology 2001, 118:277-290.
3. Avila G., O'Brien J.J., et al. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4215-4220.
4. Avila G., O'Connell K.M., et al. The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. The Journal of General Physiology 2003, 121:277-286.
5. Balschun D., Wolfer D.P., et al. Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning. The EMBO Journal 1999, 18:5264-5273.
6. Blayney L.M., Lai F.A. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacology and Therapeutics 2009, 123:151-177.
7. Boncompagni S., Rossi A.E., et al. Characterization and temporal development of cores in a mouse model of malignant hyperthermia. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21996-22001.
8. Capacchione J.F., Muldoon S.M. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesthesia and Analgesia 2009, 109:1065-1069.
9. Carpenter D., Ringrose C., et al. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Medical Genetics 2009, 10:104.
10. Censier K., Urwyler A., et al. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. Journal of Clinical Investigation 1998, 101:1233-1242.
11. Cerrone M., Colombi B., et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiacryanodine receptor. Circulation Research 2005, 96:e77-e82.
12. Chelu M.G., Goonasekera S.A., et al. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. The FASEB Journal 2006, 20:329-330.
13. Chen X., Tang T.S., et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. The Journal of Neuroscience 2008, 28:12713-12724.
14. Cherednichenko G., Ward C.W., et al. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. Molecular Pharmacology 2008, 73:1203-1212.
15. 2+ and trigger ventricular arrhythmias in mice. Circulation Research 2007, 101:617-626.
16. Crotti L., Celano G., et al. Congenital long QT syndrome. Orphanet Journal of Rare Diseases 2008, 3:18.
17. d'Amati G., Bagattin A., et al. Juvenile sudden death in a family with polymorphic ventricular arrhythmias caused by a novel RyR2 gene mutation: Evidence of specific morphological substrates. Human Pathology 2005, 36:761-767.
18. Dainese M., Quarta M., et al. Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice. The FASEB Journal 2009, 23:1710-1720.
19. Davis M.R., Haan E., et al. Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscular Disorders 2003, 13:151-157.
20. Davis P.J., Brandom B.W. The association of malignant hyperthermia and unusual disease: When you're hot you're hot or maybe not. Anesthesia and Analgesia 2009, 109:1001-1003.
21. Denborough M. Malignant hyperthermia. Lancet 1998, 352:1131-1136.
22. Denborough M.A., Lovell R.R.H. Anaesthetic deaths in a family. Lancet 1960, 276:45.
23. Dirksen R.T. Bi-directional coupling between dihydropyridine receptors and ryanodine receptors. Frontiers in Bioscience 2002, 7:d659-d670.
24. 2+ release channels?. Trends in Cardiovascular Medicine 2002, 12:189-197.
25. 2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophysical Journal 2004, 87:3193-3204.
26. Downey G.P., Rosenberg M., et al. Neuroleptic malignant syndrome. Patient with unique clinical and physiologic features. American Journal of Medicine 1984, 77:338-340.
27. Ducreux S., Zorzato F., et al. Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. The Journal of Biological Chemistry 2004, 279:43838-43846.
28. Durham W.J., Aracena-Parks P., et al. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008, 133:53-65.
29. 2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circulation Research 2009, 104:201-209. (212p following 209).
30. Ferreiro A., Monnier N., et al. A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Annals of Neurology 2002, 51:750-759.
31. Fujii J., Otsu K., et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991, 253:448-451.
32. 2+ release channel (ryanodine receptor) activity and conductance. Biophysical Journal 2000, 79:828-840.
33. George C.H., Higgs G.V., et al. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circulation Research 2003, 93:531-540.
34. 2+ release channel dysfunction. Circulation Research 2006, 98:88-97.
35. Gillard E.F., Otsu K., et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991, 11:751-755.
36. Girard T., Cavagna D., et al. B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. The Journal of Biological Chemistry 2001, 276:48077-48082.
37. Goddard C.A., Ghais N.S., et al. Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts. Acta physiologica (Oxford, England) 2008, 194:123-140.
38. Halsall P.J., Bridges L.R., et al. Should patients with central core disease be screened for malignant hyperthermia?. Journal of Neurology, Neurosurgery & Psychiatry 1996, 61:119-121.
39. Harrison G.G. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. British Journal of Anaesthesia 1975, 47:62-65.
40. 2+ channel regulation. Trends in Cardiovascular Medicine 2000, 10:310-316.
41. Isaacs H., Heffron J.J., et al. Central core disease. A correlated genetic, histochemical, ultramicroscopic, and biochemical study. Journal of Neurology. Neurosurgery and Psychiatry 1975, 38:1177-1186.
42. 2+ activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia. The Journal of Biological Chemistry 2008, 283:20813-20820.
43. 2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circulation Research 2002, 91:218-225.
44. 2+ release, but normal ryanodine receptors, in canine and human heart failure. Circulation Research 2002, 91:1015-1022.
45. 2+ release (SOICR). Proceedings of the National Academy of Sciences of the United States of America 2004, 101:13062-13067.
46. 2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circulation Research 2005, 97:1173-1181.
47. Jungbluth H. Multi-minicore Disease. Orphanet Journal of Rare Diseases 2007, 2:31.
48. Jungbluth H., Zhou H., et al. Centronuclear myopathy due to a de novo dominant mutation in theskeletal muscle ryanodine receptor (RYR1)gene. NeuromuscularDisorders 2007, 17:338-345.
49. Jungbluth H., Wallgren-Pettersson C., et al. Centronuclear (myotubular) myopathy. Orphanet Journal of Rare Diseases 2008, 3:26.
50. Jurynec M.J., Xia R., et al. Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:12485-12490.
51. Kannankeril P.J., Mitchell B.M., et al. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:12179-12184.
52. 2+ -ATPase in myotonic dystrophy type 1. Human Molecular Genetics 2005, 14:2189-2200.
53. 2+ release, and catecholaminergic polymorphic ventricular tachycardia. Journal of Clinical Investigation 2006, 116:2510-2520.
54. Kobayashi S., Yano M., et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. Journal of the American College of Cardiology 2009, 53:1993-2005.
55. Krause T., Gerbershagen M.U., et al. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004, 59:364-373.
56. Lahat H., Pras E., et al. A Missense Mutation in a Highly Conserved Region of CASQ2 Is Associated with Autosomal Recessive Catecholamine-Induced Polymorphic Ventricular Tachycardia in Bedouin Families from Israel. American Journal of Human Genetics 2001, 69:1378-1384.
57. Laitinen P.J., Brown K.M., et al. Mutations of the cardiac ryanodine receptor (RYR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001, 103:485-490.
58. Larach M.G., Gronert G.A., et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesthesia and Analgesia 2010, 110:498-507.
59. Larach M.G., Localio A.R., et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994, 80:771-779.
60. 2+ release channels in malignant hyperthermia. Biophysical Journal 1997, 73:1913-1924.
61. Leenhardt A., Lucet V., et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995, 91:1512-1519.
62. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. The Journal of Clinical Investigation 2008, 118:2230-2245.
63. Lehnart S.E., Wehrens X.H., et al. Cardiac ryanodine receptor function and regulation in heart disease. Annals of the New York Academy of Sciences 2004, 1015:144-159.
64. Lehnart S.E., Wehrens X.H.T. Sudden Death in Familial Polymorphic Ventricular Tachycardia Associated With Calcium Release Channel (Ryanodine Receptor) Leak. Circulation 2004, 109:3208-3214.
65. Liu J., Tang T.S., et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. The Journal of Neuroscience 2009, 29:9148-9162.
66. Liu N., Colombi B., et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: Insights from a RyR2 R4496C knock-in mouse model. Circulation Research 2006, 99:292-298.
67. Lohn M., Jessner W., et al. Regulation of calcium sparks and spontaneous transient outward currents by RyR3 in arterial vascular smooth muscle cells. Circulation Research 2001, 89:1051-1057.
68. 2+ release channels. The American Journal of Medicine 1998, 104:470-486.
69. 2+ release channel function and severe central core disease. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4164-4169.
70. Magee K.R., Shy G.M. A new congenital non-progressive myopathy. Brain 1956, 79:610-621.
71. Marx S.O., Reiken S., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000, 101:365-376.
72. 2+ regulation defects. Physiological Reviews 1996, 76:537-592.
73. Moghadaszadeh B., Aracena-Parks P., et al. SEPN1-related myopathy: A defect in redox regulation. In 12th International Congress of the World Muscle Society, Giardini Naxos-Taormina, Italy, 17-20 October 2007. Neuromuscular Disorders 2007, 17:899.
74. Moghadaszadeh B., Petit N., et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nature Genetics 2001, 29:17-18.
75. Monnier N., Procaccio V., et al. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. American Journal of Human Genetics 1997, 60:1316-1325.
76. Monnier N., Romero N.B., et al. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Human Molecular Genetics 2000, 9:2599-2608.
77. Monnier N., Romero N.B., et al. Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Human Molecular Genetics 2001, 10:2581-2592.
78. Monnier N., Ferreiro A., et al. A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. Human Molecular Genetics 2003, 12:1171-1178.
79. Monteforte N., Priori S.G. The long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Pacing and Clinical Electrophysiology 2009, 32(Suppl 2):S52-S57.
80. Nakajima T., Kaneko Y., et al. The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization. European Heart Journal 1997, 18:530-531.
81. Nelson M.T., Cheng H., et al. Relaxation of arterial smooth muscle by calcium sparks. Science 1995, 270:633-637.
82. Noguchi N., Yoshikawa T., et al. FKBP12.6 disruption impairs glucose-induced insulin secretion. Biochemical and Biophysical Research Communications 2008, 371:735-740.
83. Oda T., Yano M., et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 2005, 111:3400-3410.
84. 2+ release in muscle fibers of pigs susceptible to malignant hyperthermia. The American Journal of Physiology 1997, 272:C203-C211.
85. 2+ release channels. The Journal of Clinical Investigation 2005, 115:2033-2038.
86. Priori S.G., Napolitano C., et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001, 103:196-200.
87. Rampazzo A., Nava A., et al. A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Human Molecular Genetics 1995, 4:2151-2154.
88. Robinson R., Carpenter D., et al. Mutations in RYR1 in malignant hyperthermia and central core disease. Human Mutation 2006, 27:977-989.
89. Rosenberg H., Sambuughin N., et al. Malignant Hyperthermia Susceptibility In GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2010 2010, Available at:. http://www.genetests.org.
90. Sanoudou D., Beggs A.H. Clinical and genetic heterogeneity in nemaline myopathy-A disease of skeletal muscle thin filaments. Trends in Molecular Medicine 2001, 7:362-368.
91. Sato T., Nishio H., et al. Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Science International 2010, 194:77-79.
92. Sewry C.A., Muller C., et al. The spectrum of pathology in central core disease. Neuromuscular Disorders 2002, 12:930-938.
93. Shuaib A., Paasuke R.T., et al. Central core disease. Clinical features in 13 patients. Medicine (Baltimore) 1987, 66:389-396.
94. Swan H., Piippo K., et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. Journal of the American College of Cardiology 1999, 34:2035-2042.
95. 2+ leak in failing hearts. Cardiovascular Research 2009, 81:536-545.
96. Tilgen N., Zorzato F., et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Human Molecular Genetics 2001, 10:2879-2887.
97. Tiso N., Stephan D.A., et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Human Molecular Genetics 2001, 10:189-194.
98. Tobin J.R., Jason D.R., et al. Malignant hyperthermia and apparent heat stroke. JAMA: Journal of the American Medical Association 2001, 286:168-169.
99. 2+ release channels. The Journal of Biological Chemistry 1999, 274:693-702.
100. 2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. The Biochemical Journal 1994, 301(Pt 3):661-665.
101. Treves S., Jungbluth H., et al. Congenital muscle disorders with cores: The ryanodine receptor calcium channel paradigm. Current Opinion in Pharmacology 2008, 8:319-326.
102. Wallgren-Pettersson C., Jasani B., et al. Alpha-actinin in nemaline bodies in congenital nemaline myopathy: Immunological confirmation by light and electron microscopy. Neuromuscular Disorders 1995, 5:93-104.
103. Watanabe H., Chopra N., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Natural Medicines 2009, 15:380-383.
104. Wehner M., Rueffert H., et al. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clinical Genetics 2002, 62:135-146.
105. Wehrens X.H., Lehnart S.E., et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003, 113:829-840.
106. Wehrens X.H., Lehnart S.E., et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9607-9612.
107. Weiss R.G., O'Connell K.M., et al. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. American Journal of Physiology. Cell Physiology 2004, 287:C1094-C1102.
108. Wu S., Ibarra M.C., et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006, 129:1470-1480.
109. Xiao B., Jiang M.T., et al. Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. Circulation Research 2005, 96:847-855.
110. Xu L., Wang Y., et al. Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies. The Journal of Biological Chemistry 2008, 283:6321-6329.
111. Yang T., Ta T.A., et al. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. The Journal of Biological Chemistry 2003, 278:25722-25730.
112. Yang T., Riehl J., et al. Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 2006, 105:1164-1175.
113. Yano M., Kobayashi S., et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003, 107:477-484.
114. Yano M., Yamamoto T., et al. Mechanisms of disease: Ryanodine receptor defects in heart failure and fatal arrhythmia. Nature Clinical Practice. Cardiovascular Medicine 2006, 3:43-52.
115. Zhao M., Li P., et al. Molecular identification of the ryanodine receptor pore-forming segment. The Journal of Biological Chemistry 1999, 274:25971-25974.
116. Zhao X., Weisleder N., et al. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. The Journal of Biological Chemistry 2006, 281:33477-33486.
117. Zhou H., Brockington M., et al. Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. American Journal of Human Genetics 2006, 79:859-868.
118. Zhou H., Yamaguchi N., et al. Characterization of recessive RYR1 mutations in core myopathies. Human Molecular Genetics 2006, 15:2791-2803.
119. 2+ release channel function and delays development in homozygous offspring of a mutant mouse line. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:18537-18542.
120. 2+ dysregulation in RyR1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21813-21818.